CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
Metrics: PDF 416 views | Full Text 1491 views | ?
Julianne Huegel1, Christine T. Dinh2, Maria Martinelli1, Olena Bracho2, Rosa Rosario1, Haley Hardin1, Michael Estivill2, Anthony Griswold3, Sakir Gultekin4, Xue-Zhong Liu2,5 and Cristina Fernandez-Valle1
1 Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA
2 Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA
4 Department of Pathology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
5 Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL 33136, USA
Keywords: fimepinostat; Schwann cell; vestibular schwanomma; merlin; nerve allograft
Received: May 24, 2022 Accepted: June 28, 2022 Published: July 19, 2022
Neurofibromatosis Type 2 (NF2) is a rare tumor disorder caused by pathogenic variants of the merlin tumor suppressor encoded by NF2. Patients develop vestibular schwannomas (VS), peripheral schwannomas, meningiomas, and ependymomas. There are no approved drug therapies for NF2. Previous work identified phosphoinositide-3 kinase (PI3K) as a druggable target. Here we screened PI3K pathway inhibitors for efficacy in reducing viability of human schwannoma cells. The lead compound, CUDC907, a dual histone deacetylase (HDAC)/PI3K inhibitor, was further evaluated for its effects on isolated and nerve-grafted schwannoma model cells, and primary VS cells. CUDC907 (3 nM IG50) reduced human merlin deficient Schwann cell (MD-SC) viability and was 5–100 fold selective for MD over WT-SCs. CUDC907 (10 nM) promoted cell cycle arrest and caspase-3/7 activation within 24 h in human MD-SCs. Western blots confirmed a dose-dependent increase in acetylated lysine and decreases in pAKT and YAP. CUDC907 decreased tumor growth rate by 44% in a 14-day treatment regimen, modulated phospho-target levels, and decreased YAP levels. In five primary VS, CUDC907 decreased viability, induced caspase-3/7 cleavage, and reduced YAP levels. Its efficacy correlated with basal phospho-HDAC2 levels. CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.